Onconova Therapeutics Inc (ONTX) 5.70 $ONTX
Global Penile Cancer Clinical Trials Review 2014
M2 - Mon Apr 14, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jq243x/penile_cancer) has announced the addition of the "Penile Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Penile Cancer Global Clinical Trials Review, H1, 2014" provides data on the Penile Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Penile Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Penile Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Penile Cancer Therapeutics Clinical Trials - Pfizer Inc. - Onconova Therapeutics, Inc. - European Organization for Research and Treatment of Cancer - National Cancer Institute - Clinical Trial Overview of National Cancer Institute - Fondazione IRCCS - Istituto Nazionale dei Tumori - University Hospitals Bristol NHS Trust - Southwest Oncology Group - The University of Texas M. D. Anderson Cancer Center - Hoag Memorial Hospital Presbyterian - Memorial Sloan Kettering Cancer Center - FUDAN University - Institute of Cancer Research For more information visit http://www.researchandmarkets.com/research/jq...ile_cancer
Should Onconova Therapeutics (ONTX) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:56AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Onconova Therapeutics, the stock of which company has actually seen rising estimates over the past one month.
Onconova Development Programs Highlighted in Seven Presentations at AACR Annual Meeting
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of seven abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, being held April 5-9, 2014. The presentations focus on the mechanism of action of rigosertib, and two IND-track preclinical programs that target important cancer metabolism and cell division proteins.
Onconova (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:00AM CDT
Onconova (ONTX) Enters Oversold Territory
Endocyte (ECYT) Soars: Stock Adds 94.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:51AM CDT
Endocyte, Inc. was a big mover last session, as its shares rose over 94% on the day.
Why Onconova Therapeutics (ONTX) Could Be a Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:47AM CDT
Onconova Therapeutics looks well positioned for a solid gain, but has been overlooked by investors lately
Is A Short Squeeze Ahead for Onconova (ONTX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:18AM CDT
Is A Short Squeeze Ahead for Onconova (ONTX)?
Onconova (ONTX) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 6:55AM CDT
Onconova (ONTX) is now in Oversold Territory
Onconova Therapeutics, Inc. Reports Fourth Quarter and Year-End 2013 Financial Results and Outlines Key Objectives for 2014
GlobeNewswire - Mon Mar 10, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for its year ended December 31, 2013.
Onconova Therapeutics, Inc. Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call
GlobeNewswire - Tue Mar 04, 4:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's fourth quarter and year ended December 31, 2013 will be released on Monday, March 10, 2014. The Company will host a conference call and audio webcast at 4:30 PM ET on the same day.
The Zacks Analyst Blog Highlights:Isis Pharmaceuticals, Onconova Therapeutics, Vertex Pharma, Biogen and FTI Consulting
PR Newswire - Thu Feb 27, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Isis Pharmaceuticals (Nasdaq:ISIS-Free Report), Onconova Therapeutics (Nasdaq:ONTX-Free Report), Vertex Pharma (Nasdaq:VRTX-Free Report), Biogen (Nasdaq:BIIB-Free Report) and FTI Consulting, Inc. (NYSE:FCN-Free Report).
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 26, 10:35AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
Onconova Therapeutics, Inc. to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 8:22AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Cowen and Company 34 Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, March 5 at 11:20 a.m. ET.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:38AM CST
It's always fun watching the best of the best compete in the Winter Olympic games. But, of course, not everyone can win. Plenty of athletes experience the proverbial agony of defeat. That's the case with investing, too. Not every stock can be a...
Onconova's Rigosertib Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:40PM CST
Onconov's rigosertib failed to meet its primary endpoint of significant improvement in median overall survival in the ONTIME study
Why Onconova Therapeutics Inc. Shares Imploded
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 12:02PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Onconova Therapeutics , a clinical-stage...
Onconova's MDS Study Fails and I Explain What I Got Wrong.
at The Street - Thu Feb 20, 6:30AM CST
Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.
Onconova Announces Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
GlobeNewswire - Wed Feb 19, 3:01PM CST
-Rigosertib vs. Best Supportive Care did not meet the primary endpoint of statistically significant improvement in median overall survival-
Global Penile Cancer Clinical Trials Review 2014
M2 - Mon Apr 14, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jq243x/penile_cancer) has announced the addition of the "Penile Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Penile Cancer Global Clinical Trials Review, H1, 2014" provides data on the Penile Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Penile Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Penile Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Penile Cancer Therapeutics Clinical Trials - Pfizer Inc. - Onconova Therapeutics, Inc. - European Organization for Research and Treatment of Cancer - National Cancer Institute - Clinical Trial Overview of National Cancer Institute - Fondazione IRCCS - Istituto Nazionale dei Tumori - University Hospitals Bristol NHS Trust - Southwest Oncology Group - The University of Texas M. D. Anderson Cancer Center - Hoag Memorial Hospital Presbyterian - Memorial Sloan Kettering Cancer Center - FUDAN University - Institute of Cancer Research For more information visit http://www.researchandmarkets.com/research/jq...ile_cancer
Should Onconova Therapeutics (ONTX) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:56AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Onconova Therapeutics, the stock of which company has actually seen rising estimates over the past one month.
Onconova Development Programs Highlighted in Seven Presentations at AACR Annual Meeting
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of seven abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, being held April 5-9, 2014. The presentations focus on the mechanism of action of rigosertib, and two IND-track preclinical programs that target important cancer metabolism and cell division proteins.
Onconova (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:00AM CDT
Onconova (ONTX) Enters Oversold Territory
Endocyte (ECYT) Soars: Stock Adds 94.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:51AM CDT
Endocyte, Inc. was a big mover last session, as its shares rose over 94% on the day.
Why Onconova Therapeutics (ONTX) Could Be a Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:47AM CDT
Onconova Therapeutics looks well positioned for a solid gain, but has been overlooked by investors lately
Is A Short Squeeze Ahead for Onconova (ONTX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:18AM CDT
Is A Short Squeeze Ahead for Onconova (ONTX)?
Onconova (ONTX) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 6:55AM CDT
Onconova (ONTX) is now in Oversold Territory
Onconova Therapeutics, Inc. Reports Fourth Quarter and Year-End 2013 Financial Results and Outlines Key Objectives for 2014
GlobeNewswire - Mon Mar 10, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for its year ended December 31, 2013.
Onconova Therapeutics, Inc. Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call
GlobeNewswire - Tue Mar 04, 4:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's fourth quarter and year ended December 31, 2013 will be released on Monday, March 10, 2014. The Company will host a conference call and audio webcast at 4:30 PM ET on the same day.
The Zacks Analyst Blog Highlights:Isis Pharmaceuticals, Onconova Therapeutics, Vertex Pharma, Biogen and FTI Consulting
PR Newswire - Thu Feb 27, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Isis Pharmaceuticals (Nasdaq:ISIS-Free Report), Onconova Therapeutics (Nasdaq:ONTX-Free Report), Vertex Pharma (Nasdaq:VRTX-Free Report), Biogen (Nasdaq:BIIB-Free Report) and FTI Consulting, Inc. (NYSE:FCN-Free Report).
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 26, 10:35AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
Onconova Therapeutics, Inc. to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 8:22AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Cowen and Company 34 Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, March 5 at 11:20 a.m. ET.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:38AM CST
It's always fun watching the best of the best compete in the Winter Olympic games. But, of course, not everyone can win. Plenty of athletes experience the proverbial agony of defeat. That's the case with investing, too. Not every stock can be a...
Onconova's Rigosertib Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:40PM CST
Onconov's rigosertib failed to meet its primary endpoint of significant improvement in median overall survival in the ONTIME study
Why Onconova Therapeutics Inc. Shares Imploded
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 12:02PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Onconova Therapeutics , a clinical-stage...
Onconova's MDS Study Fails and I Explain What I Got Wrong.
at The Street - Thu Feb 20, 6:30AM CST
Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.
Onconova Announces Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
GlobeNewswire - Wed Feb 19, 3:01PM CST
-Rigosertib vs. Best Supportive Care did not meet the primary endpoint of statistically significant improvement in median overall survival-
